PharmaCyte Biotech Strengthens Financial Position with Femasys Monetization

PharmaCyte Biotech has successfully monetized its stake in Femasys Inc., increasing its cash and marketable securities to approximately $20 million. This move validates the company's strategic approach to capital deployment and strengthens its financial position. The transaction highlights PharmaCyte's ability to identify and execute on high-quality opportunities that deliver strong returns while maintaining a conservative risk profile.